Mechanisms of genetic regulation in gene expression: Examples from drug metabolizing enzymes and transporters

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 3, 2011, Pages 299-313

  Glubb, Dylan M ^a   Innocenti, Federico ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; ENZYME;

ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; CARRIER PROTEINS; ENZYMES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 79955938447     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.125     Document Type: Review

References (98)

1. Johnson AD,Wang D, Sadee W. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther 2005, 106:19-38.
2. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007, 26:183-201.
3. Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, Giavalisco P, Nieselt-Struwe K, Muchmore E, Varki A, Ravid R, et al. Intra- and interspecific variation in primate gene expression patterns. Science 2002, 296:340-343.
4. White RJ, Sharrocks AD. Coordinated control of the gene expression machinery. Trends Genet 2010, 26:214-220.
5. Wilkie GS, Dickson KS, Gray NK. Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci 2003, 28:182-188.
6. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463:457-463.
7. Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitinproteasome system and onto human diseases and drug targeting. Medicina (B Aires) 2010, 70:105-119.
8. McKee AE, Silver PA. Systems perspectives on mRNA processing. Cell Res 2007, 17:581-590.
9. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002, 300:355-360.
10. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002, 300:361-366.
11. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005, 78:260-277.
12. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008, 659:40-48.
13. Larsen F, Gundersen G, Lopez R, Prydz H. CpG islands as gene markers in the human genome. Genomics 1992, 13:1095-10107.
14. Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009, 85:426-430.
15. Hirota T, Takane H, Higuchi S, Ieiri I. Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Curr Drug Metab 2008, 9:34-38.
16. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 2009, 10:1067-1076.
17. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000, 10:217-223.
18. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004, 10:7100-7107.
19. Luedi PP, Dietrich FS, Weidman JR, Bosko JM, Jirtle RL, Hartemink AJ. Computational and experimental identification of novel human imprinted genes. Genome Res 2007, 17:1723-1730.
20. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, Yu W, Rongione MA, Ekstrom TJ, Harris TB, et al. Intra-individual change over time in DNA methylation with familial clustering. Jama 2008, 299:2877-2883.
21. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006, 7:181.
22. Grzybowska EA, Wilczynska A, Siedlecki JA. Regulatory functions of 3′UTRs. Biochem Biophys Res Commun 2001, 288:291-295.
23. Yang M, Li Y, Padgett RW. MicroRNAs: Small regulators with a big impact. Cytokine Growth Factor Rev 2005, 16:387-393.
24. Shomron N, Golan D, Hornstein E. An evolutionary perspective of animal microRNAs and their targets. J Biomed Biotechnol 2009, 2009:594738.
25. Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics 2010, 11:629-632.
26. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, and Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008, 76:582-588.
27. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7:2152-2159.
28. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drugresistant cells to maintain high expression of ABCG2. Mol Cancer Ther 2009, 8:2959-2968.
29. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009, 75:1374-1379.
30. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010, 79:817-824.
31. Wang L, Oberg AL, Asmann YW, Sicotte H, McDonnell SK, Riska SM, Liu W, Steer CJ, Subramanian S, Cunningham JM, et al. Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One 2009, 4:e5878.
32. Levine M, Tjian R. Transcription regulation and animal diversity. Nature 2003, 424:147-151.
33. Liu Y, Liu XS, Wei L, Altman RB, Batzoglou S. Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res 2004, 14:451-458.
34. Ludwig MZ. Functional evolution of noncoding DNA. Curr Opin Genet Dev 2002, 12:634-639.
35. Wingender E, Dietze P, Karas H, Knuppel R. TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996, 24:238-241.
36. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 2004, 32:D91-D94.
37. Orphanides G, Reinberg D. A unified theory of gene expression. Cell 2002, 108:439-451.
38. Teufel A, Weinmann A, Krupp M, Budinger M, Galle PR. Genome-wide analysis of factors regulating gene expression in liver. Gene 2007, 389:114-121.
39. Pennacchio LA, Loots GG, Nobrega MA, Ovcharenko I. Predicting tissue-specific enhancers in the human genome. Genome Res 2007, 17:201-211.
40. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005, 94: 1169-1686.
41. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, Ishikawa T. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 2006, 21:437-457.
42. Kang HS, Angers M, Beak JY, Wu X, Gimble JM, Wada T, Xie W, Collins JB, Grissom SF, Jetten AM. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 2007, 31:281-294.
43. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, et al. Global variation in copy number in the human genome. Nature 2006, 444:444-454.
44. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315:848-853.
45. Armengol L, Villatoro S, Gonzalez JR, Pantano L, Garcia-AragonesM, Rabionet R, Caceres M, Estivill X. Identification of copy number variants defining genomic differences among major human groups. PLoS One 2009, 4:e7230.
46. Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, Pittard WS, Devine SE. An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res 2006, 16:1182-1190.
47. Crawford DC, Akey DT, and Nickerson DA. The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005, 6:287-312.
48. Wakabayashi-Nakao K, Tamura A, Furukawa T,Nakagawa H, Ishikawa T. Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. Adv Drug Deliv Rev 2009, 61:66-72.
49. Duan J, Antezana MA. Mammalian mutation pressure, synonymous codon choice, and mRNA degradation. J Mol Evol 2003, 57:694-701.
50. Capon F, Allen MH, Ameen M, Burden AD, Tillman D, Barker JN, Trembath RC. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13:2361-2368.
51. Lavner Y, Kotlar D. Codon bias as a factor in regulating expression via translation rate in the human genome. Gene 2005, 345:127-138.
52. Kimchi-Sarfaty C,Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
53. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004, 26:180-185.
54. Modafferi EF, Black DL. A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon. Mol Cell Biol 1997, 17:6537-6545.
55. Selvakumar M, Helfman DM. Exonic splicing enhancers contribute to the use of both 3′ and 5′ splice site usage of rat beta-tropomyosin pre-mRNA. RNA 1999, 5:378-394.
56. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, et al. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 2009, 4:e6942.
57. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 2008, 40:317-354.
58. Hines RN, Koukouritaki SB, Poch MT, Stephens MC. Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition. Drug Metab Rev 2008, 40:263-301.
59. Beutler E,Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998, 95:8170-8174.
60. Ramirez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, Innocenti F. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J 2008, 8:152-161.
61. Yoder Graber AL, Ramirez J, Innocenti F, and Ratain MJ. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics 2007, 17:619-627.
62. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-1388.
63. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy 2008, 28:755-768.
64. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME. Identification of genetic variants contributing to cisplatininduced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007, 81:427-437.
65. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S, Dolan ME. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008, 68:3161-3168.
66. Huang RS, Duan S, Kistner EO, Zhang W, Bleibel WK, Cox NJ, Dolan ME. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics 2008, 18:545-549.
67. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008, 84: 417-423.
68. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, De Jager PL, Shaw SY, Wolfish CS, Slavik JM, Cotsapas C, et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 2008, 4:e1000287.
69. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Gutierrez Arcelus M, Sekowska M, et al. Common regulatory variation impacts gene expression in a cell typedependent manner. Science 2009, 325:1246-1250.
70. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008, 6:e107.
71. Bullaughey K, Chavarria CI, Coop G, Gilad Y. Expression quantitative trait loci detected in cell lines are often present in primary tissues. Hum Mol Genet 2009, 18:4296-4303.
72. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP and Copy number Annotation. Bioinformatics 2010, 26:259-262.
73. Serre D, Gurd S, Ge B, Sladek R, Sinnett D, Harmsen E, Bibikova M, Chudin E, Barker DL, Dickinson T, et al. Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cisacting mechanisms regulating gene expression. PLoS Genet 2008, 4:e1000006.
74. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L, Samaha RR. Large-scale real-time PCR validation on gene expression measurements from two commercial longoligonucleotide microarrays. BMC Genomics 2006, 7:59.
75. Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, Richmond TA, Middle CM, Rodesch MJ, Packard CJ, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods 2007, 4:903-905.
76. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
77. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 2008, 18:1509-1517.
78. Pang GS, Wang J, Wang Z, Lee CG. Predicting potentially functional SNPs in drug-response genes. Pharmacogenomics 2009, 10:639-653.
79. Mooney SD, Krishnan VG, Evani US. Bioinformatic tools for identifying disease gene and SNP candidates. Methods Mol Biol 2010, 628:307-319.
80. Knight JC. Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond) 2003, 104:493-501.
81. Himes SR, Shannon MF. Assays for transcriptional activity based on the luciferase reporter gene. Methods Mol Biol 2000, 130:165-174.
82. Yang WS, Nevin DN, Iwasaki L, Peng R, Brown BG, Brunzell JD, Deeb SS. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res 1996, 37:2627-2637.
83. Buratowski S, Chodosh LA. Mobility shift DNAbinding assay using gel electrophoresis. Curr Protoc Mol Biol 2001, 2(suppl 36):12.2.1-12.2.11.
84. Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Pena-Castillo L, Alleyne TM, Mnaimneh S, Botvinnik OB, Chan ET, et al. Variation in homeodomain DNA binding revealed by highresolution analysis of sequence preferences. Cell 2008, 133:1266-1276.
85. Warren CL, Kratochvil NC, Hauschild KE, Foister S, Brezinski ML, Dervan PB, Phillips GN Jr, Ansari AZ. Defining the sequence-recognition profile of DNAbinding molecules. Proc Natl Acad Sci U S A 2006, 103:867-872.
86. Massie CE, Mills IG. Chromatin immunoprecipitation (ChIP) methodology and readouts. Methods Mol Biol 2009, 505:123-137.
87. Das PM, Ramachandran K. vanWert J, Singal R. Chromatin immunoprecipitation assay. Biotechniques 2004, 37:961-969.
88. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci U S A 2006, 103:1406-1411.
89. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latencymodel for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002, 99:95-100.
90. Pillai S, Chellappan SP. ChIP on chip assays: genomewide analysis of transcription factor binding and histone modifications. Methods Mol Biol 2009, 523:341-366.
91. Gilchrist DA, Fargo DC, Adelman K. Using ChIP-chip and ChIP-seq to study the regulation of gene expression: genome-wide localization studies reveal widespread regulation of transcription elongation. Methods 2009, 48:398-408.
92. van der Meer DL, Degenhardt T, Vaisanen S, de Groot PJ, Heinaniemi M, de Vries SC, Muller M, Carlberg C, Kersten S. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res 2010, 38:2839-2850.
93. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet 2009, 10:669-680.
94. Cui JY, Choudhuri S, Knight TR, Klaassen CD. Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver. Toxicol Sci 2010, 116:32-43.
95. Maynard ND, Chen J, Stuart RK, Fan JB, Ren B. Genome-wide mapping of allele-specific protein-DNA interactions in human cells. Nat Methods 2008, 5:307-309.
96. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009, 18:3758-3768.
97. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
98. Ising M, Lucae S, Binder EB, Bettecken T, UhrM, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, et al. A genomewide association study points tomultiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009, 66:966-975.